数据
资源
版本对比
免费注册
预约演示
免费注册
Prostate Cancer
Pipeline Insights: Comprehensive Analysis of Key Emerging Therapies and Pharmaceutical Companies
2021-03-23
·
GlobeNewswire
小分子药物
Los Angeles, USA, March 22, 2021 (GLOBE NEWSWIRE) --
Prostate Cancer
Pipeline Insights: Comprehensive Analysis of Key Emerging Therapies and Pharmaceutical Companies With over 900 key pharmaceutical companies working, the
Prostate cancer
pipeline projects a robust and promising picture in near future, says DelveInsight DelveInsight’s ‘
Prostate Cancer
Pipeline Insights’ report highlights major breakthroughs happening in the domain, emerging therapies in different stages of clinical development, segmented based on MoA, RoA, molecule types, drug delivery platform, and so on. Some of the key highlights from the
Prostate Cancer
Drug Pipeline report: Request for Sample @
Prostate Cancer
Therapeutic Assessment
Prostate cancer
originates from the prostate gland located in the pelvis, next to the bladder, of men. It is the second-leading cause of death due to
cancers
in men in the U.S. About 1 in 9 men are diagnosed with
prostate cancer
in their lifetime. Growths in the prostate can be benign (not
cancer
) or malignant (
cancer
).
Prostate Cancer
Drug Profiles
Tomivosertib
: Effector Therapeutics
Tomivosertib
(also known as
eFT508
) is a novel, potent and highly selective oral small molecule inhibitor of mitogen-activated protein kinase interacting kinases 1 and 2, or collectively,
MNK1/2
.
MNK1/2
plays a crucial role in the development of many
tumors
, including by controlling in a coordinated manner the expression of multiple factors that attenuate an immune response.
Tomivosertib
is currently in the Phase II stage of development. This Phase 2 study examines the efficacy, safety, tolerability, and pharmacokinetics (PK) of
eFT508
(
tomivosertib
) in
metastatic castration-resistant prostate cancer
patients who have documented
PSA
PSA
progression on treatment with one of three hormone therapies –
abiraterone
,
enzalutamide
or
apalutamide
and for whom no curative therapy exists. The primary objective of this study is to assess the anti-
tumor
response to
eFT508 (tomivosertib)
in mCRPC. Gain more rich insights into drug profiles, trials, stages @
Prostate cancer
drug pipeline
Prostate Cancer
Emerging Drugs Profile at a Glance
Prostate Cancer
Therapeutic Assessment By Product Type By Stage By Route of
Administration
By Molecule Type By Mechanism of
Action
By Targets By Stage and Molecule TypeBy Stage and Route of AdministrationBy Stage and Product Type Get a holistic view of the pipeline analysis @
Prostate Cancer
Drug Pipeline and Emerging Trends Scope of the Report Coverage: GlobalKey Players:
Pfizer
,
Myovant Biosciences
,
Effector Therapeutics
,
Mediolanum
, Merck,
ESSA Pharma
,
Sanofi
,
Astellas Pharma
,
AstraZeneca
,
Bayer
,
Janssen research & development LLC
,
Bristol Myers Squibb
,
Eli Lilly and Company
,
Amgen
,
POINT Biopharma
, Hinnova Pharmaceuticals,
Sophiris Bio
,
Ultimovacs
,
Foresee Pharmaceuticals
,
Luye Pharma Group
,
Abbott, AB
science,
Ferring pharmaceuticals
,
Jiangsu HengRui Medicine
,
Hoffmann-La Roche
,
Novartis
,
Celgene
,
Endocyte
,
Millennium Pharmaceuticals
, Medivation,
Veru
,
Progenics Pharmaceuticals
,
Boehringer Ingelheim
,
US Biotest
,
Antev
,
Elevation oncology
,
Abgenix
,
Astellas Pharma
,
Orion Pharma
,
Clovis Oncology
, Exelixis, Takeda,
Novus Therapeutics
,
Candel Therapeutics
,
Ipsen
,
MEI Pharma
,
Aragon Pharmaceuticals
,
MedImmune
,
CytRx
,
Tmunity Therapeutics
,
Inovio Pharmaceuticals
,
Forma Therapeutics
,
Luye Pharma
,
Health Ever Bio-Tech
,
Advaxis
,
Corcept Therapeutics
, and several others. Key Questions Answered Got queries? Get answers @
Prostate Cancer
Emerging Therapies Table of Contents Reach out for a live demo of the report @
Prostate Cancer
Pipeline Insights Related Reports
Prostate Cancer
MarketDelveInsight's "
Prostate cancer
Market Insights, Epidemiology, and Market Forecast-2030" report.
Cervical Cancer
MarketDelveInsight’s ‘
Cervical Cancer
–Market Insights, Epidemiology, and Market Forecast-2030’ report.
Multiple Myeloma
MarketDelveInsight’s ‘
Multiple Myeloma
(MM)-Market Insights, Epidemiology and Market Forecast—2030’ report. Acral
Lentiginous Melanoma
MarketDelveInsight's "
Acral lentiginous melanoma
Market Insights, Epidemiology, and Market Forecast-2030" report.
Acute Lymphoblastic Leukemia
MarketDelveInsight's "
Acute Lymphoblastic Leukemia
Market Insights, Epidemiology, and Market Forecast-2030" report.
Acute Myeloid Leukemia
MarketDelveInsight's "
Acute Myeloid Leukemia (AML)
Market Insights, Epidemiology, and Market Forecast-2030" report.
Adenoid Cystic Carcinoma
MarketDelveInsight's "
Adenoid Cystic Carcinoma
Market Insights, Epidemiology, and Market Forecast-2030" report. Adult
T Cell Leukemia Lymphoma
MarketDelveInsight's "
Adult T-Cell Leukemia-Lymphoma
- Market Insights, Epidemiology, and Market Forecast-2030" report.
Advanced Liver Cancer
MarketDelveInsight's "
Advanced Liver Cancer
- Market Insights, Epidemiology, and Market Forecast-2030" report. Advanced
Melanoma
MarketDelveInsight's "Advanced Melanoma - Market Insights, Epidemiology, and Market Forecast-2030" report.
Advanced Pancreatic Cancer
MarketDelveInsight's "
Advanced Pancreatic Cancer
- Market Insights, Epidemiology, and Market Forecast-2030" report.
Advanced Recurrent Ovarian Cancer
MarketDelveInsight's "
Advanced Recurrent Ovarian Cancer
- Market Insights, Epidemiology, and Market Forecast-2030" report.
AIDS-Related Kaposi’s Sarcoma
MarketDelveInsight's "
AIDS-Related Kaposi's Sarcoma
- Market Insights, Epidemiology, and Market Forecast-2030" report. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports
Pharma
companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
机构
Corcept Therapeutics, Inc.
Boehringer Ingelheim GmbH
Pharma Technology SA
[+49]
适应症
前列腺癌
肿瘤
转移性去势抵抗性前列腺癌
[+12]
靶点
MNK1
NPEPPS
药物
Tomivosertib
醋酸阿比特龙
恩扎卢胺
[+1]
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务